Background: The hepatitis C virus (HCV) may be an important explanation for hepatic pathology, cirrhosis, and hepatocellular carcinoma. The aim of the study wasto assess the liver stiffness before and after oral antiviral medication in chronic viral hepatitis c patients attending Zagazig University Hospitals. Methods: This study included forty three Egyptian patients with HCV  infection diagnosed by  HCV RNA  real time quantitative PCR  whose ages  were ranged from 29-71 , All patients took   anti-viral treatment according to the rules of the committee responsible for hepatitis c virus control in Egypt. Treatment regimens included: Sofosbuvir, daclatasvir and ribavirin (RBV). The patients were collected and followed up in the period between April 2017 and August 2018. , radiological tool liver transient elastography (TE) and laboratory tests APRI, FIB4 test were done for all patients.Results: There were  improvements  in liver stiffness measurements,APRI,FIB4 test hemoglobin, fasting blood sugar  , platelets count, and ALT, AST levels  in patients who achieved a 48-week sustained infectious agent response. The failure to achieve improvement within the level of liver stiffness was related to treatment failure. Conclusions:  Treatment with sofosbuvir drug regimen makes significant decrease in liver stiffness measurements and fibrosis indices.